Actively Recruiting

Phase Not Applicable
Age: 18Years - 40Years
All Genders
NCT07368764

The Suitability of Tience® for Treating Acne Scars

Led by Linio Biotech Oy · Updated on 2026-01-28

20

Participants Needed

1

Research Sites

87 weeks

Total Duration

On this page

Sponsors

L

Linio Biotech Oy

Lead Sponsor

C

Clinius Ltd

Collaborating Sponsor

AI-Summary

What this Trial Is About

This is an open-label, single-center, split-face, pseudo-randomized clinical trial designed to evaluate the efficacy and safety of a human-derived, cell-free adipose tissue derivative (Tience® ), for treating moderate to severe acne scars. Participants will receive three treatment sessions over a three-month period: on Day 0, Day 30, and Day 90. Treatment will be administered via injections to acne-scarred areas on one side of the face. The untreated side will be treated after the follow-up period. Outcomes will be evaluated over a twelve-month period using investigator clinical assessments, patient self-evaluation and VISIA skin analysis system to monitor changes in scar severity and overall skin quality.

CONDITIONS

Official Title

The Suitability of Tience® for Treating Acne Scars

Who Can Participate

Age: 18Years - 40Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Healthy volunteers aged 18 to 40 years
  • Have acne scars on their cheeks that are at least 3 years old
Not Eligible

You will not qualify if you...

  • Pregnancy or nursing
  • Cancer or ongoing cancer treatment
  • Active skin disease
  • Fitzpatrick skin type 4 to 6
  • Use of strong medications for severe acne (e.g., Isotretinoin)
  • Active acne or Herpes
  • Use of antihistamine medication unless it can be paused for 7 days during study visits
  • Use of biological medications
  • Tendency for excessive scar formation
  • Tendency for urticaria (hives)
  • Use of systemic medication affecting immunity
  • Autoimmune disease
  • Known blood clotting disorders (e.g., von Willebrand disease)
  • Allergy to the study product or its ingredients
  • Smoking

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Aava Kamppi Medical Centre

Helsinki, Finland, 001000

Actively Recruiting

Loading map...

Research Team

M

Minna Höst, Coordinator

CONTACT

L

Laura Bouchard, MD, PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here